In the london report it states "Zoptrex™, a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer. As the rate of death in the trial is lower than expected, Aeterna Zentaris now expects to complete the Phase 3 clinical trial by the end of the year with results following early in 2017, "
but previous in the 6/6/16 pr it was stated "Pivotal Phase III Trial for Endometrial Cancer Expected to be Completed in Q3 2016
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”) today reconfirmed its commitment to LHRH-receptor targeted therapy and its expectation that the pivotal, phase 3 trial for Zoptrex™ (zoptarelin doxorubicin) in women with advanced, recurrent endometrial cancer, is expected to be completed in the third quarter of 2016."
How did we lose a full quarter and why?
Market Data 
Markets 
AI
